Frontlight ResearchEarly access
Active, not recruitingNo phase
A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)
Key facts
- Who runs it
- Boston Scientific Corporation
- Where
- Atlanta, Boston, Carlsbad, Charleston, Chicago, Elk Grove Village, Eugene, Fort Lauderdale, Gainesville, Kansas City, Lancaster, Larkspur, Murrells Inlet, New York, Overland Park, Post Falls, Rancho Mirage, Seattle, Spokane, Tyler, Walnut Creek, Waycross, and Ypsilanti, United StatesSee the 23 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 166 people enrolled
- Started
- 30 Jan 2020
- Expected to end
- Feb 2041
- Type of study
- Interventional
- Treatments tested
- Superion™ IDS device
- Record updated
- 12 November 2026
Who can take part
- Age
- 45 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- 45 years of age or older when written informed consent is obtained
- Persistent leg/buttock/groin pain, with or without back pain that is consistently relieved by flexion activities (example: sitting or bending over a shopping cart)
- Diagnosis of degenerative spinal stenosis of the lumbar spine, defined as the narrowing of the midline sagittal spinal canal (central) and/or narrowing between the facet superior articulating process (SAP), the posterior vertebral margin (lateral access), and the nerve root canal (foraminal)
- Subject signed a valid, IRB-approved informed consent form (ICF) provided in English
- Subjects, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, cooperate with the investigational procedures and are willing to return for all the required post-treatment follow-ups
- Able to independently read and complete all questionnaires and assessments provided in English
Who cannot take part
- Participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study
- Has any pain-related diagnosis, medical/psychological condition or external factors that, in the investigator's medical judgment, might confound reporting of study outcomes (e.g. history of pelvic pain, anginal pain, chronic migraine, involved in litigation, workmen's compensation, spinal tumor)
- Axial back pain only
- Fixed motor deficit in lower extremity(ies) due to LSS
Where in United States
- Alliance Spine and Pain CentersAtlanta, United States
- Brigham and Women's HospitalBoston, United States
- Coastal Research Institute, LLCCarlsbad, United States
- The Spine and Nerve Center of Saint Francis HospitalCharleston, United States
- Rush University Medical CenterChicago, United States
- Ascension Alexian BrothersElk Grove Village, United States
- Pacific Sports and Spine, LLCEugene, United States
- Holy Cross HospitalFort Lauderdale, United States
- The Orthopaedic InstituteGainesville, United States
- University of Kansas HospitalKansas City, United States
- Center for Interventional Pain and SpineLancaster, United States
- MarinHealth Spine InstituteLarkspur, United States
- SC Pain and Spine SpecialistsMurrells Inlet, United States
- Weill Cornell Medical UniversityNew York, United States
- Neuroscience Research Center, LLCOverland Park, United States
- North Idaho Day SurgeryPost Falls, United States
- Vitamed ResearchRancho Mirage, United States
- Swedish Health ServicesSeattle, United States
- Northwest Pain CareSpokane, United States
- Precision Spine CareTyler, United States
- IPM Medical Group Inc.Walnut Creek, United States
- Centurion Spine and PainWaycross, United States
- Michigan Pain SpecialistsYpsilanti, United States
About the trial
What the trial wants to find out
To compile real-world outcomes of the Superion™ IDS in routine clinical practice.
The group in the trial
- Superion™ IDS deviceTreatment being tested
Superion™ Indirect Decompression System (IDS)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 12 November 2026